We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
251
Smartleaf Asset Management
Massachusetts
– -$1.83K -107 Closed
ASN
252
Advisory Services Network
Georgia
– -$4.22K -105 Closed
Mitsubishi UFJ Asset Management
253
Mitsubishi UFJ Asset Management
Japan
– -$3.9K -97 Closed
BBHC
254
Brown Brothers Harriman & Co
New York
– -$3.82K -95 Closed
FFA
255
Farther Finance Advisors
California
– -$3.84K -95 Closed
SWM
256
SHP Wealth Management
Massachusetts
– -$3.1K -77 Closed
EP
257
Essential Partners
California
– -$2.78K -69 Closed
HI
258
Harbour Investments
Wisconsin
– -$2.72K -67 Closed
S
259
Sachetta
Massachusetts
– -$2.41K -60 Closed
CAL
260
Capital Analysts LLC
Pennsylvania
– -$2K -57 Closed
TPCW
261
TD Private Client Wealth
New York
– -$2.25K -56 Closed
FMII
262
Farmers & Merchants Investments Inc
Nebraska
– -$2.01K -50 Closed
NB
263
NBT Bank
New York
– -$1.81K -45 Closed
MCM
264
Manchester Capital Management
Vermont
– -$1.13K -28 Closed
HI
265
Horizon Investments
North Carolina
– -$966 -24 Closed
TPWA
266
Twin Peaks Wealth Advisors
California
– -$966 -24 Closed
SPIA
267
Steward Partners Investment Advisory
New York
– -$925 -23 Closed
CMA
268
Cedar Mountain Advisors
Oregon
– -$724 -18 Closed
CT
269
Clearstead Trust
Maine
– -$725 -18 Closed
TWD
270
True Wealth Design
Ohio
– -$644 -16 Closed
RFP
271
Root Financial Partners
California
– -$483 -12 Closed
KFAS
272
Keating Financial Advisory Services
Kansas
– -$443 -11 Closed
MCM
273
MV Capital Management
Maryland
– -$242 -6 Closed
WA
274
WPG Advisers
Maryland
– -$201 -5 Closed
FISPB
275
Fideuram - Intesa Sanpaolo Private Banking
– -$161 -4 Closed
8 9 10
11
12

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.